PRESCRIBING INFORMATION 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
FLOVENT® HFA 44 mcg
(fluticasone propionate HFA 44 mcg)
Inhalation Aerosol
FLOVENT® HFA 110 mcg
(fluticasone propionate HFA 110 mcg)
Inhalation Aerosol
FLOVENT® HFA 220 mcg
(fluticasone propionate HFA 220 mcg)
Inhalation Aerosol
For Oral Inhalation Only
DESCRIPTION
The active component of FLOVENT HFA 44 mcg Inhalation Aerosol, FLOVENT HFA
110 mcg Inhalation Aerosol, and FLOVENT HFA 220 mcg Inhalation Aerosol is fluticasone
propionate, a corticosteroid having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-
dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, 17-propionate and the
following chemical structure:
22
23
24
25
26
27
28
29
30
31
32
33
Fluticasone propionate is a white to off-white powder with a molecular weight of 500.6, and
the empirical formula is C25H31F3O5S. It is practically insoluble in water, freely soluble in
dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.
FLOVENT HFA 44 mcg Inhalation Aerosol, FLOVENT HFA 110 mcg Inhalation Aerosol,
and FLOVENT HFA 220 mcg Inhalation Aerosol are pressurized, metered-dose aerosol units
intended for oral inhalation only. Each unit contains a microcrystalline suspension of fluticasone
propionate (micronized) in propellant HFA-134a (1,1,1,2-tetrafluoroethane). It contains no other
excipients.
After priming, each actuation of the inhaler delivers 50, 125, or 250 mcg of fluticasone
propionate in 60 mg of suspension (for the 44-mcg product) or in 75 mg of suspension (for the
1
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
110- and 220-mcg products) from the valve and 44, 110, or 220 mcg, respectively, of fluticasone
propionate from the actuator. The actual amount of drug delivered to the lung may depend on
patient factors, such as the coordination between the actuation of the device and inspiration
through the delivery system.
Each 10.6-g canister (44 mcg) and each 12-g canister (110 and 220 mcg) provides
120 inhalations.
FLOVENT HFA should be primed before using for the first time by releasing 4 test sprays
into the air away from the face, shaking well before each spray. In cases where the inhaler has
not been used for more than 7 days or when it has been dropped, prime the inhaler again by
shaking well and releasing 1 test spray into the air away from the face.
This product does not contain any chlorofluorocarbon (CFC) as the propellant.
CLINICAL PHARMACOLOGY
Mechanism of Action: Fluticasone propionate is a synthetic trifluorinated corticosteroid with
potent anti-inflammatory activity. In vitro assays using human lung cytosol preparations have
established fluticasone propionate as a human corticosteroid receptor agonist with an affinity 18
times greater than dexamethasone, almost twice that of beclomethasone-17-monopropionate
(BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of
budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these
results. The clinical significance of these findings is unknown.
Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have
been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes,
macrophages, and neutrophils) and mediator production or secretion (e.g., histamine,
eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These
anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma.
Though effective for the treatment of asthma, corticosteroids do not affect asthma symptoms
immediately. Individual patients will experience a variable time to onset and degree of symptom
relief. Maximum benefit may not be achieved for 1 to 2 weeks or longer after starting treatment.
When corticosteroids are discontinued, asthma stability may persist for several days or longer.
Studies in patients with asthma have shown a favorable ratio between topical
anti-inflammatory activity and systemic corticosteroid effects with recommended doses of orally
inhaled fluticasone propionate. This is explained by a combination of a relatively high local
anti-inflammatory effect, negligible oral systemic bioavailability (<1%), and the minimal
pharmacological activity of the only metabolite detected in man.
Preclinical: Propellant HFA-134a is devoid of pharmacological activity except at very high
doses in animals (i.e., 380 to 1,300 times the maximum human exposure based on comparisons of
area under the plasma concentration versus time curve [AUC] values), primarily producing
ataxia, tremors, dyspnea, or salivation. These events are similar to effects produced by the
structurally related CFCs, which have been used extensively in metered-dose inhalers.
2
In animals and humans, propellant HFA-134a was found to be rapidly absorbed and rapidly
eliminated, with an elimination half-life of 3 to 27 minutes in animals and 5 to 7 minutes in
humans. Time to maximum plasma concentration (T
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
max) and mean residence time are both
extremely short, leading to a transient appearance of HFA-134a in the blood with no evidence of
accumulation.
Pharmacokinetics: Absorption: Fluticasone propionate acts locally in the lung; therefore,
plasma levels do not predict therapeutic effect. Studies using oral dosing of labeled and
unlabeled drug have demonstrated that the oral systemic bioavailability of fluticasone propionate
is negligible (<1%), primarily due to incomplete absorption and presystemic metabolism in the
gut and liver. In contrast, the majority of the fluticasone propionate delivered to the lung is
systemically absorbed. Systemic exposure as measured by AUC in healthy subjects (N = 24)
who received 8 inhalations, as a single dose, of fluticasone propionate HFA using the 44-, 110-,
and 220-mcg strengths increased proportionally with dose. The geometric means (95% CI) of
AUC0-24 hr for the 44-, 110-, and 220-mcg strengths were 488 (362, 657); 1,284 (904; 1,822); and
2,495 (1,945; 3,200) pg•hr/mL, respectively, and the geometric means of Cmax were 126 (108,
148), 254 (202, 319), and 421 (338, 524) pg/mL, respectively. Systemic exposure from
fluticasone propionate HFA 220 mcg was 30% lower than that from the CFC-propelled
fluticasone propionate inhaler. Systemic exposure was measured in subjects with asthma who
received 2 inhalations of fluticasone propionate HFA 44 mcg (n = 20), 110 mcg (n = 15), or
220 mcg (n = 17) twice daily for at least 4 weeks. The geometric means (95% CI) of AUC0-12 hr
for the 44-, 110-, and 220-mcg strengths were 76 (33, 175), 298 (191, 464), and 601 (431, 838)
pg•hr/mL, respectively. Cmax occurred in about 1 hour, and the geometric means were 25 (18,
36), 61 (46, 81), and 103 (73, 145) pg/mL, respectively.
Distribution: Following intravenous administration, the initial disposition phase for
fluticasone propionate was rapid and consistent with its high lipid solubility and tissue binding.
The volume of distribution averaged 4.2 L/kg.
The percentage of fluticasone propionate bound to human plasma proteins averages 91%.
Fluticasone propionate is weakly and reversibly bound to erythrocytes and is not significantly
bound to human transcortin.
Metabolism: The total clearance of fluticasone propionate is high (average, 1,093 mL/min),
with renal clearance accounting for less than 0.02% of the total. The only circulating metabolite
detected in man is the 17β-carboxylic acid derivative of fluticasone propionate, which is formed
through the cytochrome P450 3A4 pathway. This metabolite had less affinity (approximately
1/2,000) than the parent drug for the corticosteroid receptor of human lung cytosol in vitro and
negligible pharmacological activity in animal studies. Other metabolites detected in vitro using
cultured human hepatoma cells have not been detected in man.
Elimination: Following intravenous dosing, fluticasone propionate showed polyexponential
kinetics and had a terminal elimination half-life of approximately 7.8 hours. Less than 5% of a
radiolabeled oral dose was excreted in the urine as metabolites, with the remainder excreted in
the feces as parent drug and metabolites.
3
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
Special Populations: Hepatic Impairment: Since fluticasone propionate is
predominantly cleared by hepatic metabolism, impairment of liver function may lead to
accumulation of fluticasone propionate in plasma. Therefore, patients with hepatic disease
should be closely monitored.
Pediatric: Two pharmacokinetic studies evaluated the systemic exposure to fluticasone
propionate at steady state in children with asthma aged 4 to 11 years following inhalation of
fluticasone propionate HFA. In an open-label, multiple-dose, 2-period crossover study, 13
children aged 4 to 11 years received 88 mcg of fluticasone propionate HFA twice daily for
7.5 days in one period and 88 mcg of CFC-propelled fluticasone propionate twice daily for
7.5 days in the other period. The geometric means (95% CI) of AUC(last) were 28 pg•hr/mL (10,
80) following fluticasone propionate HFA and 65 pg•hr/mL (27, 153) following CFC-propelled
fluticasone propionate, indicating that systemic exposure was 55% lower using fluticasone
propionate HFA. The geometric means (95% CI) of Cmax were 15.1 pg/mL (8.5, 27) following
fluticasone propionate HFA and 20.4 pg/mL (13, 32) following CFC-propelled fluticasone
propionate; indicating that Cmax was 26% lower using fluticasone propionate HFA. Tmax was
similar for both treatments. AUClast and Cmax in this pediatric population were 37% and 60%,
respectively, of those in adult patients receiving the same dose.
In a second open-label, single-dose, 2-period crossover study, 21 children with asthma aged 5
to 11 years received 264 mcg of fluticasone propionate HFA administered with and without an
AeroChamber Plus™ Valved Holding Chamber (VHC). The geometric means (95% CI) of
AUClast were 261 pg•hr/mL (252, 444) with the use of the VHC and 40 pg•hr/mL (16, 208)
without the VHC. The geometric means (95% CI) of Cmax were 52 pg/mL (46, 70) with the VHC
and 19 pg/mL (17, 41) without the VHC. The median Tmax was 1 hour with or without the VHC.
Therefore, systemic exposure was higher with the VHC in these pediatric patients with asthma.
Gender: Systemic exposure for 19 male and 33 female subjects with asthma from
2 inhalations of CFC-propelled fluticasone propionate 44, 110, and 220 mcg twice daily was
similar.
Other: Formal pharmacokinetic studies using fluticasone propionate have not been
conducted in other special populations.
Drug Interactions: Fluticasone propionate is a substrate of cytochrome P450 3A4.
Coadministration of fluticasone propionate and the highly potent cytochrome P450 3A4 inhibitor
ritonavir is not recommended based upon a multiple-dose, crossover drug interaction study in 18
healthy subjects. Fluticasone propionate aqueous nasal spray (200 mcg once daily) was
coadministered for 7 days with ritonavir (100 mg twice daily). Plasma fluticasone propionate
concentrations following fluticasone propionate aqueous nasal spray alone were undetectable
(<10 pg/mL) in most subjects, and when concentrations were detectable, peak levels (Cmax)
averaged 11.9 pg/mL (range, 10.8 to 14.1 pg/mL) and AUC(0-τ) averaged 8.43 pg•hr/mL (range,
4.2 to 18.8 pg•hr/mL). Fluticasone propionate Cmax and AUC(0-τ) increased to 318 pg/mL (range,
110 to 648 pg/mL) and 3,102.6 pg•hr/mL (range, 1,207.1 to 5,662.0 pg•hr/mL), respectively,
after coadministration of ritonavir with fluticasone propionate aqueous nasal spray. This
4
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
significant increase in plasma fluticasone propionate exposure resulted in a significant decrease
(86%) in plasma cortisol AUC.
Caution should be exercised when other potent cytochrome P450 3A4 inhibitors are
coadministered with fluticasone propionate. In a drug interaction study, coadministration of
orally inhaled fluticasone propionate (1,000 mcg) and ketoconazole (200 mg once daily) resulted
in increased plasma fluticasone propionate exposure and reduced plasma cortisol AUC, but had
no effect on urinary excretion of cortisol.
In another multiple-dose drug interaction study, coadministration of orally inhaled fluticasone
propionate (500 mcg twice daily) and erythromycin (333 mg 3 times daily) did not affect
fluticasone propionate pharmacokinetics.
Similar definitive studies with fluticasone propionate HFA were not performed, but results
should be independent of the formulation and drug delivery device.
Pharmacodynamics: Serum cortisol concentrations, urinary excretion of cortisol, and urine
6-β-hydroxycortisol excretion collected over 24 hours in 24 healthy subjects following
8 inhalations of fluticasone propionate HFA 44, 110, and 220 mcg decreased with increasing
dose. However, in subjects with asthma treated with 2 inhalations of fluticasone propionate HFA
44, 110, and 220 mcg twice daily for at least 4 weeks, differences in serum cortisol AUC(0-12 hr)
concentrations (N = 65) and 24-hour urinary excretion of cortisol (N = 47) compared with
placebo were not related to dose and generally not significant. In the study with healthy
volunteers, the effect of propellant was also evaluated by comparing results following the
220-mcg strength inhaler containing HFA 134a propellant with the same strength of inhaler
containing CFC 11/12 propellant. A lesser effect on the hypothalamic-pituitary-adrenal (HPA)
axis with the HFA formulation was observed for serum cortisol, but not urine cortisol and
6-betahydroxy cortisol excretion. In addition, in a crossover study of children with asthma aged
4 to 11 years (N = 40), 24-hour urinary excretion of cortisol was not affected after a 4-week
treatment period with 88 mcg of fluticasone propionate HFA twice daily compared with urinary
excretion after the 2-week placebo period. The ratio (95% CI) of urinary excretion of cortisol
over 24 hours following fluticasone propionate HFA versus placebo was 0.987 (0.796, 1.223).
The potential systemic effects of fluticasone propionate HFA on the HPA axis were also
studied in patients with asthma. Fluticasone propionate given by inhalation aerosol at dosages of
440 or 880 mcg twice daily was compared with placebo in oral corticosteroid-dependent subjects
with asthma (range of mean dose of prednisone at baseline, 13 to 14 mg/day) in a 16-week study.
Consistent with maintenance treatment with oral corticosteroids, abnormal plasma cortisol
responses to short cosyntropin stimulation (peak plasma cortisol <18 mcg/dL) were present at
baseline in the majority of subjects participating in this study (69% of patients later randomized
to placebo and 72% to 78% of patients later randomized to fluticasone propionate HFA). At
week 16, 8 subjects (73%) on placebo compared to 14 (54%) and 13 (68%) subjects receiving
fluticasone propionate HFA (440 and 880 mcg b.i.d., respectively) had post-stimulation cortisol
levels of <18 mcg/dL.
5
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
To confirm that systemic absorption does not play a role in the clinical response to inhaled
fluticasone propionate, a double-blind clinical study comparing inhaled fluticasone propionate
powder and oral fluticasone propionate was conducted. Fluticasone propionate inhalation powder
in dosages of 100 and 500 mcg twice daily was compared to oral fluticasone propionate
20,000 mcg once daily and placebo for 6 weeks. Plasma levels of fluticasone propionate were
detectable in all 3 active groups, but the mean values were highest in the oral group. Both
dosages of inhaled fluticasone propionate were effective in maintaining asthma stability and
improving lung function, while oral fluticasone propionate and placebo were ineffective. This
demonstrates that the clinical effectiveness of inhaled fluticasone propionate is due to its direct
local effect and not to an indirect effect through systemic absorption.
CLINICAL TRIALS
Adolescent and Adult Patients: Three randomized, double-blind, parallel-group,
placebo-controlled clinical trials were conducted in the US in 980 adolescent and adult patients
(≥12 years of age) with asthma to assess the efficacy and safety of FLOVENT HFA in the
treatment of asthma. Fixed dosages of 88, 220, and 440 mcg twice daily (each dose administered
as 2 inhalations of the 44-, 110-, and 220-mcg strengths, respectively) and 880 mcg twice daily
(administered as 4 inhalations of the 220-mcg strength) were compared with placebo to provide
information about appropriate dosing to cover a range of asthma severity. Patients in these
studies included those inadequately controlled with bronchodilators alone (Study 1), those
already receiving inhaled corticosteroids (Study 2), and those requiring oral corticosteroid
therapy (Study 3). In all 3 studies, patients (including placebo-treated patients) were allowed to
use VENTOLIN® (albuterol, USP) Inhalation Aerosol as needed for relief of acute asthma
symptoms. In Studies 1 and 2, other maintenance asthma therapies were discontinued.
Study 1 enrolled 397 patients with asthma inadequately controlled on bronchodilators alone.
FLOVENT HFA was evaluated at dosages of 88, 220, and 440 mcg twice daily for 12 weeks.
Baseline FEV1 values were similar across groups (mean 67% of predicted normal). All 3 dosages
of FLOVENT HFA significantly improved asthma control as measured by improvement in AM
pre-dose FEV1 compared with placebo. Pulmonary function (AM pre-dose FEV1) improved
significantly with FLOVENT HFA compared with placebo after the first week of treatment, and
this improvement was maintained over the 12-week treatment period.
At Endpoint (last observation), mean change from baseline in AM pre-dose percent predicted
FEV1 was greater in all 3 groups treated with FLOVENT HFA (9.0% to 11.2%) compared with
the placebo group (3.4%). The mean differences between the groups treated with
FLOVENT HFA 88, 220, and 440 mcg and the placebo group were significant, and the
corresponding 95% confidence intervals were (2.2%, 9.2%), (2.8%, 9.9%), and (4.3%, 11.3%),
respectively.
Figure 1 displays results of pulmonary function tests (mean percent change from baseline in
FEV1 prior to AM dose) for the recommended starting dosage of FLOVENT HFA (88 mcg twice
daily) and placebo from Study 1. This trial used predetermined criteria for lack of efficacy
6
(indicators of worsening asthma), resulting in withdrawal of more patients in the placebo group.
Therefore, pulmonary function results at Endpoint (the last evaluable FEV
230
231
232
233
234
235
236
237
1 result, including
most patients’ lung function data) are also displayed.
Figure 1. A 12-Week Clinical Trial in Patients ≥12 Years of Age Inadequately
Controlled on Bronchodilators Alone: Mean Percent Change From Baseline
in FEV1 Prior to AM Dose (Study 1)
238
239
240
241
242
243
本文档为【FLOVENT HFA (fluticasone propionate HFA) Inhalation Aerosol】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。